SCHEMBL22119640

SCHEMBL22119640

CCOC(=O)CCN(C(N)=O)c1cccc(C2CCN(C(=O)O)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
OPRM1 P35372 3/20 0.39
BRD4 O60885 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
PDE4B Q07343 1/20 0.37
OPRD1 P41143 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 3/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
TP53 P04637 1/20 0.36
F2 P00734 1/20 0.35
F10 P00742 1/20 0.35
HTT P42858 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
PARP10 Q53GL7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22119549 0.88 TP53 (0.43) SMN1; SMN2PDE4BKMT2AMAPTMEN1
SCHEMBL30087126 0.88 TP53 (0.43) SMN1; SMN2PDE4BKMT2AMAPTMEN1
SCHEMBL22119779 0.88 OPRM1 (0.42) SMN1; SMN2OPRM1BRD4PDE4BNPC1
SCHEMBL22119622 0.84 SMN1; SMN2 (0.39) SMN1; SMN2OPRM1BRD4PDE4BOPRD1
SCHEMBL22119800 0.76 GPR119 (0.45) SMN1; SMN2PDE4BKMT2AMAPTMEN1
SCHEMBL22119623 0.76 NPC1 (0.43) NPC1KMT2A
SCHEMBL22119472 0.73 OPRM1 (0.38) SMN1; SMN2OPRM1BRD4PDE4BNPC1
SCHEMBL3154927 0.73 NPY2R (0.48) BRD4MAPTALDH1A1
SCHEMBL22119474 0.73 TP53 (0.43) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL30086984 0.73 TP53 (0.43) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
EP-4168407-A1 BRAF DEGRADERS C4 Therapeutics, Inc. (US) 2023-04-26 EP disclosed
WO-2021255212-A1 BRAF DEGRADERS F. HOFFMANN-LA ROCHE AG (CH) 2021-12-23 WO disclosed
EP-3897631-A1 TARGETED PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2021-10-27 EP disclosed
WO-2020132561-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 SMN1; SMN2 3020/4885OPRM1 4748/4885BRD4 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.